Published in Vaccine Weekly, June 18th, 2008
The full report is available at http://www.BeaconEquity.com.
Anyone interested in receiving alerts regarding TapImmune Inc. research should e-mail email@example.com with "TPIM" in the subject line.
In the report, the analyst writes, "The Company recently received positive news from the U.S. Patent office regarding key follow on patents and has also filed additional patent applications that further strengthen and expand its IP portfolio ...
"TPIM also benefits from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.